| Title |
Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749)
|
|---|---|
| Published in |
BMC Cancer, June 2014
|
| DOI | 10.1186/1471-2407-14-411 |
| Pubmed ID | |
| Authors |
Michael Tachezy, Florian Gebauer, Cordula Petersen, Dirk Arnold, Martin Trepel, Karl Wegscheider, Phillipe Schafhausen, Maximilian Bockhorn, Jakob Robert Izbicki, Emre Yekebas |
| Abstract |
Median OS after surgery in curative intent for non-metastasized pancreas cancer ranges under study conditions from 17.9 months to 23.6 months. Tumor recurrence occurs locally, at distant sites (liver, peritoneum, lungs), or both. Observational and autopsy series report local recurrence rates of up to 87% even after potentially "curative" R0 resection. To achieve better local control, neoadjuvant CRT has been suggested for preoperative tumour downsizing, to elevate the likelihood of curative, margin-negative R0 resection and to increase the OS rate. However, controlled, randomized trials addressing the impact of neoadjuvant CRT survival do not exist. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 99 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 99 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 11% |
| Other | 10 | 10% |
| Student > Bachelor | 10 | 10% |
| Researcher | 9 | 9% |
| Student > Postgraduate | 7 | 7% |
| Other | 21 | 21% |
| Unknown | 31 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 42 | 42% |
| Nursing and Health Professions | 8 | 8% |
| Agricultural and Biological Sciences | 2 | 2% |
| Neuroscience | 2 | 2% |
| Mathematics | 1 | 1% |
| Other | 5 | 5% |
| Unknown | 39 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 March 2015.
All research outputs
#13,409,581
of 22,757,090 outputs
Outputs from BMC Cancer
#2,968
of 8,276 outputs
Outputs of similar age
#111,334
of 228,688 outputs
Outputs of similar age from BMC Cancer
#51
of 136 outputs
Altmetric has tracked 22,757,090 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,276 research outputs from this source. They receive a mean Attention Score of 4.3. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 228,688 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 136 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.